May. 14 at 1:54 PM
$PTN $RYTM
This was a positive update in my opinion making Palatin even more desirable as an acquisition target which is my investment thesis… here’s why:
Palatin’s pivot to advancing a highly selective, next-generation MC4R agonist directly addresses the primary clinical shortcomings—such as daily dosing and hyperpigmentation—of current first-generation therapies. By prioritizing a "best-in-class" profile with weekly injections and oral delivery, they are positioning their pipeline as an essential life-cycle management tool for incumbent (RYTM) or an entry point for Big Pharma. The investment thesis for a micro-cap biotech like Palatin is not the high-risk, high-cost path of independent commercialization, but rather creation of a de-risked, superior asset that acts as a strategic "must-have." IMO their value thus SP upside lies in being a turnkey acquisition target, offering BP a reinforced moat and a clear path to market dominance in the multi-billion dollar rare obesity space.
